R&D Trends

Study: Large enterprises view business transformation as essential

Thursday, November 6, 2014 12:41 PM

Continual business transformation is crucial for companies to stay ahead of emerging players and maintain a competitive edge. From bringing new offerings to market to deploying IT systems to major capital expenditures, business transformation can take countless forms. Many large institutions, however, are struggling with their transformation efforts, according to a study from Oracle, a multinational computer technology corporation headquartered in Redwood City, Calif., and Forbes.

More... »


AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014 12:31 PM

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

More... »


Proteostasis Therapeutics, Astellas form $1.2B collaboration

Wednesday, November 5, 2014 12:54 PM

Proteostasis Therapeutics, a Cambridge, Mass.-based company developing novel therapeutics to address diseases caused by defects in protein folding, trafficking and clearance, and Astellas Pharma have entered into a worldwide R&D collaboration for therapeutic candidates that modulate the unfolded protein response (UPR) through the use of Proteostasis Therapeutics’ proprietary Disease Relevant Translation (DRT) and Proteostasis Network platform.

More... »

Report: Biosimilars could create $44B in healthcare savings

Wednesday, November 5, 2014 12:52 PM

Introducing competing biosimilar versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the U.S. by $44 billion over the next decade, according to a new analysis from RAND, a Boston, Mass.-based nonprofit research organization that develops solutions to public policy challenges.

More... »

LEO Pharma, Japan Tobacco ink license agreement for JTE-052

Wednesday, November 5, 2014 12:47 PM

LEO Pharma and Japan Tobacco (JT) have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052, for topical use in dermatological indications worldwide, excluding Japan where JT retains rights.

More... »

Dana-Farber Cancer Institute, Astellas form research collaboration

Wednesday, November 5, 2014 12:45 PM

Dana-Farber Cancer Institute and Astellas Pharma have inked a three-year R&D collaboration for small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.

More... »

AstraZeneca, Pharmacyclics, Janssen partner

Wednesday, November 5, 2014 12:37 PM

AstraZenecaPharmacyclics and Janssen R&D have entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with imbruvica (ibrutinib), an oral Bruton's tyrosine kinase inhibitor, co-developed and co-commercialized by Pharmacyclics and Janssen Biotech. The study will assess the combination as a treatment for patients with hematologic cancers including diffuse large B-cell lymphoma and follicular lymphoma, which are investigational uses for both compounds.

More... »

ALS Association triples spending on research thanks to ice bucket donations

Monday, November 3, 2014 02:44 PM

Thanks to the summer’s Ice Bucket Challenge donations, the ALS Association will be tripling the amount of money it spends on amyotrophic lateral sclerosis (ALS) research. The funds also will support the association’s Certified Treatment Centers of Excellence, which provide evidence-based, multi-disciplinary ALS care and services in a supportive atmosphere with an emphasis on hope and quality of life.

More... »

Cleveland Clinic unveils Top 10 Medical Innovations for 2015

Monday, November 3, 2014 02:41 PM

Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education, has announced its 9th annual list of Top 10 Medical Innovations likely to have major impact on improving patient care in 2015. The list of up-and-coming technologies and drug therapies was selected by a panel of 110 Cleveland Clinic physicians and scientists. The Top 10 Medical Innovations for 2015 are:

More... »

Novo Nordisk invests $126M in new Denmark diabetes research labs

Monday, November 3, 2014 02:38 PM

Novo Nordisk has invested approximately $126 million in new laboratories at the company's R&D campus in Måløv, Denmark. Construction has started, and the new laboratory facility is expected to be ready in early 2016.

More... »

CenterWatch
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs